Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Another Top Sanofi Exec Resigns, As Purging of Old Guard Continues

The purging of the old guard installed by former chief exec Chris Viehbacher continued at French drugmaker Sanofi (SNY) Monday, when the firm’s global head for prostate cancer drug Jevtana, Zhen Su, left to find work outside the company. The company did not issue a release on Su’s departure but the press learned about it […]

Read More »

GlaxoSmithKline Shareholders Are Willing to Give CEO Time to Revive Company: Report

Despite sagging stock prices, major investors in U.K.-based GlaxoSmithKline (GSK) indicated yesterday they are willing to give company CEO Andrew Witty time to turn the company’s fortunes around—but probably not too much time. GSK did not respond to a request for a statement in time for deadline. The Financial Times reported that shareholders have decided […]

Read More »

Amgen Dumps AstraZeneca PLC Pact After Patients Developed Suicidal Thoughts

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE:AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was […]

Read More »

How Pricey Specialty Drugs Spurred CVS’ Omnicare Deal

When drugs cost $1,000 a pill or $25,000 for a year of injections, insurers and employers want to make sure these prescriptions are being taken at the right place and at the right time and have the right outcome for the patient. After all, trends in insurance payment from private insurers as well as government […]

Read More »

Genentech Opens New Bay Area Green Building to House Up to 1,500 Workers

May 22, 2015By Mark Terry, Breaking News Staff On Thursday May 21, Genentech (RHHBY) had a ribbon-cutting ceremony for the opening of Building 35, a 255,000-square-foot that will be the site for the company’s product development and bioinformatics units. Genentech did not respond to a request for an interview in time for deadline. Genentech […]

Read More »

Amgen ends partnership with AstraZeneca on psoriasis drug

Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.   Amgen said such safety concerns would likely result in a restrictive label that could limit the number of patients using the late-stage experimental drug, brodalumab. The company […]

Read More »

Mylan CEO Says Pfizer Should Come Calling, As Next Big Deal Speculation Swirls

The speculation surrounding which big deal Pfizer Inc. (PFE) is likely to do in this white hot market reached another level Friday, after Mylan Executive Chairman Robert Coury said he viewed Pittsburgh, Penn.-based Mylan Inc. as a good fit for Pfizer if his company is successful in buying smaller generic drugmaker Perrigo Company (PRGO). Pfizer […]

Read More »

As Market Roars, Gilead Looking for Value-Added Deals, Says CFO

Booming biotech Gilead Sciences, Inc. (GILD) is looking for “value-added” deals as opposed to ones that create synergies, the company’s chief financial officer told attendees at the UBS 2015 Global Healthcare Conference in New York this week, renewing speculation that Gilead may be looking to buy a large pharmaceutical operation with an existing research and […]

Read More »

Strides Arcolab Limited Ponies Up $299.90 Million for Aspen Pharmacare’s Drug Brands

Indian drugmaker Strides Arcolab Limited is widening its portfolio of generics, saying Thursday it will buy Aspen Pharmacare Ltd.’s Australian unit for around $300 million. Strides said the deal is slated to close by the end of the second quarter. Aspen is a South African pharmaceutical company and the sale today pushes Strides and its […]

Read More »

Stock Soars as bluebird bio Gives Sneak Peak at Promising Sickle Cell Data

bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association Presenting new and updated data from HGB-205 study in beta-thalassemia major and severe sickle cell disease, including first patient with sickle cell disease ever treated with gene therapy   Company to host investor call on Monday, June 15, 2015 at 8:00 […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom